Nutex Health Inc (NUTX) Peer Comparison
$200.24
$5.04
(2.58%)
As on 11-Sep-2026 16:00EDT
Market cap
$1,323 Mln
Revenue (TTM)
$847 Mln
P/E Ratio
7.5
P/B Ratio
3.4
Div. Yield
0 %
Edit
| Nutex Health Inc (NUTX) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Avantor (AVTR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
1,323 | 12,650 | 10,638 | 9,762 | 10,125 |
Revenue ($ Mln) |
847 | 1,505 | 613 | 2,589 | 6,561 |
Net Profit ($ Mln) |
179.92 | 160.59 | -188.05 | 222.40 | -578.00 |
Net Margin (%) |
21.25 | 10.67 | -30.68 | 8.59 | -8.81 |
RoE (%) |
24.14 | 10.86 | -28.10 | 3.04 | -10.33 |
Price to Earnings |
7.49 | 79.29 | -- | 44.47 | -- |
Price-To-Book |
3.43 | 8.31 | 15.27 | 1.36 | 1.76 |
Income Statement ($ Mln)
| Nutex Health Inc (NUTX) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
846.72 | 1,504.87 | 612.84 | 2,589.30 | 6,561.10 |
|
Cost of Revenue
|
412.69 | 483.98 | 127.96 | 1,245.50 | 4,473.00 |
|
Gross Profit
|
444.28 | 942.44 | 393.22 | 1,343.60 | 2,139.40 |
|
Operating Expenses
|
69.76 | 833.56 | 565.37 | 1,108.90 | 2,373.70 |
|
Operating Profit (EBIT)
|
364.27 | 187.34 | -80.49 | 235.00 | -285.60 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
343.48 | 203.83 | -192.83 | 350.40 | -472.00 |
|
Provision for Tax
|
70.99 | 43.24 | -4.79 | 128.00 | 106.00 |
|
Profit after Tax (Net Income)
|
179.92 | 160.59 | -188.05 | 222.40 | -578.00 |
|
Minority Interest
|
-92.57 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 93.19 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Nutex Health Inc (NUTX) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
394.32 | 1,530.77 | 682.49 | 7,173.90 | 5,630.20 |
|
Minority Interest
|
-92.57 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
340.10 | 210.18 | 135.71 | 2,116.80 | 4,583.70 |
|
Current Liabilities
|
117.22 | 233.78 | 102.33 | 961.30 | 1,382.00 |
|
Total Liabilities
|
918.53 | 1,826.52 | 893.49 | 10,576.50 | 11,794.70 |
Assets ($ Mln)
| Nutex Health Inc (NUTX) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
378.98 | 630.60 | 404.74 | 7,231.50 | 9,133.70 |
|
Current Assets
|
585.65 | 1,344.12 | 515.78 | 3,020.50 | 2,462.20 |
|
Total Assets
|
918.53 | 1,826.52 | 893.49 | 10,576.50 | 11,794.70 |
|
Total Debt*
|
347.34 | 212.71 | 102.84 | 1,203.70 | 3,697.80 |
|
Net Current Assets
|
468.43 | 1,110.35 | 413.45 | 2,059.20 | 1,080.20 |
Cashflow ($ Mln)
| Nutex Health Inc (NUTX) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
248.13 | 238.66 | -46.34 | 532.20 | 623.80 |
|
Cash Flow from Investing Activities
|
-5.24 | -404.59 | -77.61 | -189.70 | -130.50 |
|
Cash from Financing Activities
|
-97.95 | 26.53 | 11.89 | -283.20 | -409.40 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Nutex Health Inc (NUTX) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
12.13 | 11.76 | -22.53 | 8.98 | -5.43 |
|
ROE (%)
|
24.14 | 10.86 | -28.10 | 3.04 | -10.33 |
|
ROA (%)
|
16.99 | 7.95 | -18.00 | 2.02 | -4.08 |
|
EBIT Margin (%)
|
42.91 | 13.63 | -30.58 | -5.99 | -4.47 |
|
Net Margin (%)
|
21.25 | 10.67 | -30.68 | 8.59 | -8.81 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Nutex Health Inc (NUTX) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
6.88 | 17.55 | 41.55 | 1.37 | -1.57 |
|
EBIT Growth (%)
|
96.05 | 17.49 | -116.42 | -131.06 | -129.16 |
|
Net Profit Growth (%)
|
260.96 | 8.72 | -102.66 | -30.32 | -184.08 |
|
EPS Growth (%)
|
135.41 | 8.12 | -96.88 | -29.66 | -184.11 |
|
Book Value Growth (%)
|
57.44 | 17.33 | -12.65 | 2.19 | -9.82 |
Valuation Ratios
| Nutex Health Inc (NUTX) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
16.69 | 68.93 | -34.59 | -- | -14.68 |
|
Price / Book Value
|
3.59 | 8.58 | 9.90 | -- | 1.40 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
4.69 | 53.25 | -43.50 | -- | 81.94 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Nutex Health Inc (NUTX) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.08 | 0.00 | 0.00 | 0.11 | 0.65 |
|
Short term debt to equity ratio
|
0.05 | 0.01 | 0.00 | 0.06 | 0.01 |
|
Current Ratio
|
5.00 | 5.75 | 5.04 | 3.14 | 1.78 |
|
Quick Ratio
|
4.96 | 3.86 | 4.46 | 2.33 | 1.18 |
|
Interest Coverage
|
18.36 | 157.91 | -38.31 | 8.18 | -1.64 |
Operating Efficiency Ratios
| Nutex Health Inc (NUTX) | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Avantor (AVTR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
42.13 | 12.65 | 22.67 | 17.06 | 17.36 |
|
Asset Turnover
|
0.80 | 0.74 | 0.59 | 0.24 | 0.46 |
|
Receivable days
|
117.15 | 46.54 | 60.95 | 65.39 | 58.79 |
|
Inventory Days
|
2.42 | 331.92 | 193.84 | 221.09 | 64.13 |
|
Payable days
|
26.66 | 26.16 | 60.19 | 37.02 | 58.13 |
|
Cash Conversion Cycle
|
92.91 | 352.30 | 194.60 | 249.46 | 64.79 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
